Mabwell has established an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation. The international standard drug discovery platforms and skillful & efficient development platforms enable us to develop innovative biologics efficiently and submit IND rapidly. We focus on large-scale, fast-growing therapeutic areas including auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Mabwell has 14 pipeline products. Of these, 2 products have been approved and commercialized, 2 products have been filed for MA approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects.
Compliant with GMP requirements in China, U.S., and Europe
Integrated production capacity of monoclonal antibodies, fusion proteins, ADCs and other drug molecules to support clinical research and commercial manufacturing
53,400㎡ (13 Acres)
Capable of providing drug samples for pre-clinical & early phase clinical use (200L, antibody production; 500g, ADC production)
Scaling up production in the kilogram can meet the production needs of critical clinical to commercialization
QA & QC capabilities (under construction)
Capable of trial production
Capacity: 8,000L, antibody production; 4,000L, recombinant protein production
Have passed EU QP Audit
69,700 ㎡ (17 Acres)
Over 27,000L capacity
Distributed Control System greatly improves the automation of liquid preparation process
Full-automatic 3D warehouse to meet smart inventory management
The integration of automation and informatization to achieve digitalization
Trial production of 2 drug substance lines (6*2,000L) + 1 drug product filling line will be carried out soon
Market led, Medical-driven, Access first
Deeply engaged in academic promotion in autoimmune diseases, metabolic diseases and oncology, we have built mature and professional marketing network in China, bringing world-class novel therapeutic options to more domestic patients. Our marketing management team is led by professionals with over 20 years of experience in average.
Improve Global Health
We are expanding to Euramerican market and emerging markets to meet the clinical needs of patients worldwide, and have entered into strategic partnerships with more than a dozen countries overseas.
2023.1 - Entered into an agreement with DISC MEDICINE (NASDAQ: IRON) about 9MW3011 (R&D code in the US: MWTX-001, MWTX-002 & MWTX-003) with a total of up to $412.5 million of down payment and milestone payment.
2021.5 - Reached a strategic cooperation with Yangtze River Pharmaceutical Group on the rights and interests of two novel biological drugs (8MW0511 & 9MW1111) in China. Both parties will share future commercial benefits within the scope of cooperation.
Partnership in emerging market
Get in touch with our BD team: firstname.lastname@example.org
2024.1 - Established a licensing and commercialization agreement to market of denosumab products in Indonesia
2023.11 - Established partnership with Innobic (wholly owned subsidiary of PTT Public Company Ltd, the state-owned enterprise and the largest company by market capitalization on Thailand Stock Exchange) to market products in Thailand
2023.10 - Established partnership with UPL to market 9MW0113 in Argentina
2023.9 - Established partnership with Legrand to market 9MW0311 & 9MW0321 in Colombia and Ecuador
2023.8 - Established partnership with UNILAB (ranks number 1 in the ASEAN pharmaceutical industry) to market 9MW0113 in the Philippines
2023.7 - Established partnership with Sothema (the biggest pharmaceutical company in Morocco) to market 9MW0113 in Morocco
2023.7 - Established partnership with Searle (one of the top pharmaceutical companies in Pakistan) to market 9MW0311 & 9MW0321 in Pakistan
2023.6 - Established a licensing and commercialization agreement of 9MW0311 & 9MW0321 for Egypt market